Corrections to “Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”

Ann Oncol 2017; 28: iv22–iv40 (doi:10.1093/annonc/mdx224) In “Table 6. Recommended choice of treatment options within TNM risk category of primary rectal cancer without distant metastases” (rows 3 and 4, column 3) Surgery (TME) alone is a standard only if good quality mesorectal resection assured (and local recurrence ≤ 0.5% or, if not, preoperative SCPRT (5 x 5 Gy) or CRT followed by TME Preoperative SCPRT (5 x 5cGy) or CRT followed by TME, depending on need for regression Is replaced with: Surgery (TME) alone is a standard only if good quality mesorectal resection assured (and local recurrence ≤ 5% or, if not, preoperative SCPRT (5 x 5 Gy) or CRT followed by TME Preoperative SCPRT (5 x 5 Gy) or CRT followed by TME, depending on need for regression Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of OncologyVol. 28PreviewThe incidence of rectal cancer in the European Union is ∼125 000 per year, i.e. ∼35% of the total colorectal cancer incidence, reflecting 15–25 cases/100 000 population per year and is predicted to increase further in both genders. The mortality is 4–10/100 000 population per year. Median age at diagnosis is ∼70 years, but predictions suggest that this figure will rise in the future. Full-Text PDF Open Archive